



Article

# Controlling the Glycosylation Profile in mAbs Using Time-Dependent Media Supplementation

Devesh Radhakrishnan <sup>1</sup>, Anne S. Robinson <sup>2</sup> and Babatunde A. Ogunnaike <sup>1,\*</sup>

- Department of Chemical and Biomolecular Engineering, University of Delaware, Newark, DE 19716, USA; devesh@udel.edu
- Department of Chemical and Biomolecular Engineering, Tulane University, New Orleans, LA 70118, USA; asr@tulane.edu
- \* Correspondence: ogunnaike@udel.edu; Tel.: +1-302-831-4504

Received: 16 October 2017; Accepted: 15 December 2017; Published: 21 December 2017

Abstract: In order to meet desired drug product quality targets, the glycosylation profile of biotherapeutics such as monoclonal antibodies (mAbs) must be maintained consistently during manufacturing. Achieving consistent glycan distribution profiles requires identifying factors that influence glycosylation, and manipulating them appropriately via well-designed control strategies. Now, the cell culture media supplement, MnCl<sub>2</sub>, is known to alter the glycosylation profile in mAbs generally, but its effect, particularly when introduced at different stages during cell growth, has yet to be investigated and quantified. In this study, we evaluate the effect of time-dependent addition of MnCl<sub>2</sub> on the glycan profile quantitatively, using factorial design experiments. Our results show that MnCl<sub>2</sub> addition during the lag and exponential phases affects the glycan profile significantly more than stationary phase supplementation does. Also, using a novel computational technique, we identify various combinations of glycan species that are affected by this dynamic media supplementation scheme, and quantify the effects mathematically. Our experiments demonstrate the importance of taking into consideration the time of addition of these trace supplements, not just their concentrations, and our computational analysis provides insight into what supplements to add, when, and how much, in order to induce desired changes.

Keywords: cell culture; glycosylation; media supplementation; MnCl<sub>2</sub>; controllability analysis

#### 1. Introduction

The global market for pharmaceuticals is predicted to grow to \$1.5 trillion by 2021, with biologics such as monoclonal antibodies (mAbs), hormones, and therapeutic enzymes accounting for nearly 20% of the market share, based on current projections. With US sales rising from \$8.29 billion in 2005 to \$24.6 billion in 2012 [1,2]—coupled with the increase in regulatory agencies approvals of mAb treatments for different indications ranging from cancer to rheumatoid arthritis and Crohn's disease [3,4], the growing market for mAbs has resulted in active development of these biological products. While several different mammalian cell expression systems can be used to synthesize mAb therapeutics, over half of all currently approved mAbs are produced in Chinese Hamster Ovary (CHO) cell lines. CHO cells are the preferred host for a large number of recombinant mAb therapeutics because of the ease of adapting them to suspension growth, and the availability of powerful gene amplification systems to improve specific productivity [5]. However, more importantly, the post-translational modification machinery in CHO cells produces human-like structures in mAbs, thus ensuring biocompatibility.

One important post-translational modification in mAbs is N-glycosylation, a process by which an oligosaccharyltransferase complex in the endoplasmic reticulum adds a sugar substrate (glycan) to the Asn-X-Ser/Thr motif in the heavy chain of the mAb (where X is any amino acid other than Pro). As the

Antibodies 2018, 7, 1 2 of 21

mAb traverses the Golgi complex, the core glycan undergoes a series of non-template driven reactions that are mediated by the localized glycosyltransferase enzymes in the different Golgi compartments [6,7]. The result is a heterogeneous distribution of glycan residues or glycoforms, which affects the immunogenicity, effector functions, and the pharmacokinetic properties of the mAb, and consequently the final drug product quality [8–10]. Thus, there is considerable motivation for manufacturers and regulators to understand, characterize, and, if necessary, modulate the glycoform distribution in mAbs during production, in order to maintain a consistent glycan profile [11–14]. However, manipulating the glycan distribution effectively requires (i) identifying the factors that can influence the glycan distribution; (ii) quantifying the degree to which these factors affect the concentration of the glycoform species; and (iii) using such information to design effective control systems.

Previous studies have demonstrated that protein glycosylation can be influenced by various factors [15], such as pH [16,17], temperature [18–20], dissolved oxygen [21,22], ammonia [23], and media supplements such as nucleotide sugar precursors [24] and manganese chloride (MnCl<sub>2</sub>) [25–28]. Each study focused on an individual factor, establishing empirical relationships between the individual factor in question and the specific set of glycan species it affects. However, modulating the complete glycan distribution profile requires manipulating multiple input factors simultaneously, and to be effective, such action must be based on a thorough, holistic understanding of how these inputs individually and jointly affect various glycan species. Such process understanding can be generated systematically by using statistical design of experiments whereby input factors are judiciously varied simultaneously to generate data on the main and interaction effects they exert on all the output responses of interest. Such structural information indicates which inputs to manipulate, and by how much, in order to alter the relative concentrations of different glycan species appropriately. In most cases, however, the available inputs are fewer than the glycan species to be controlled, resulting in a system with insufficient degrees of freedom. Consequently, we must first answer a fundamental question: given a limited set of inputs, to what extent can we independently control the concentrations of all the desired glycan species? In other words, is the desired change in the glycan distribution achievable using the available inputs? We address this question using "controllability analysis", by which we can determine quantitatively the extent to which the system is controllable. (Informally, a system is considered completely controllable if it is possible to drive the complete set of outputs from some initial value to any arbitrarily specified final, desired value, by manipulating the available set of inputs.) We have previously introduced, in [29], the concept of output controllability, demonstrated how to use it to assess the controllability of the glycan reaction network using data generated from statistical design of experiments, and in [30] we illustrated practical applicability by using it to identify in an experimental system, the glycan species whose concentrations can be controlled using such media supplements as MnCl<sub>2</sub>, galactose and NH<sub>4</sub>Cl as manipulated variables.

The role of different media supplements in modulating critical quality attributes of the mAb in general, and the glycan distribution profile in particular, has received considerable attention recently [31]. Typically, supplements such as MnCl<sub>2</sub>, which are known to affect the expression and activity of several glycosyltransferase enzymes, are added to the media at the start of the batch to alter the glycan distribution. However, over the course of the batch run, as the cells continue to grow and produce mAb molecules, it is clear that changes in the cellular availability of supplements will influence not just the antibody productivity but also the activity of the glycosyltransferase enzymes, thus affecting the final glycan distribution. Consequently, we postulate that it is possible to control the glycosylation profile in mAbs by introducing specific media supplements at different stages of cell growth. We postulate further that introducing a chelating agent to the media can alter the effect of MnCl<sub>2</sub> addition on the glycan distribution. Consequently, a chelating agent such as EDTA provides an additional degree of freedom for fine-tuning the effect of MnCl<sub>2</sub>, the media supplement of primary interest. Although EDTA is toxic to cells and can titrate both Mn<sup>++</sup> and other bivalent ions in the medium that are necessary for cell growth and may be cofactors for other glycosyltransferase enzymes, it has been used in this study primarily to elucidate the effects of a dynamic addition of the two media

Antibodies 2018, 7, 1 3 of 21

supplements. (It is important to stress that the proposed time-dependent media supplementation is distinct from current fed-batch strategies where the objective is primarily to meet the nutrient demand in the culture, for the express purpose of enhancing cell growth and productivity—not to ensure that the product quality meets specific targets.) Specifically, we aim to identify the glycan species that can be controlled by adding MnCl<sub>2</sub> during lag, exponential, and stationary phases of cell growth, and to quantify the effect of such time-dependent MnCl<sub>2</sub> additions on the glycan distribution.

In this work, we use a mixed factorial experimental design to add MnCl<sub>2</sub> and EDTA at various stages of cell growth and, via appropriate analysis of the resulting data, we quantify the effect of time-dependent media supplementation on the antibody productivity and the glycosylation profile in mAbs. Subsequently, we use controllability analysis to identify the glycan species whose relative percentages can be controlled effectively by introducing MnCl<sub>2</sub> and EDTA to the media at different time points, and quantify the effect of these time-dependent additions. Overall, our results highlight the importance of taking into account the dynamic nature of media supplementation, and also provide concepts that can be exploited to develop new strategies for controlling the glycosylation profile in mAbs.

#### 2. Materials and Methods

#### 2.1. Cell Culture

All experiments were conducted using an IgG1 producing CHO-K1 cell line donated by Genentech, San Francisco, California. The cells were scaled up in a custom CD OptiCHO<sup>TM</sup> medium formulation (Thermo Fisher Scientific, Waltham, MA, USA) that was supplemented with 4 mM glutamine, 5 g/L glucose and 25 nM MTX. The osmolality was adjusted to 300 mOsm by adding NaCl stock solution. The concentration of MnCl<sub>2</sub> in the media was adjusted using a 0.5 M stock solution (Sigma Aldrich, St. Louis, MO, USA). Similarly, a 0.5 M EDTA sterile stock solution was prepared and added to the media as required. The cells were inoculated with an initial seeding density of  $0.5 \times 10^6$  cells/mL in vented-cap Erlenmeyer shake flasks with a working volume of 50 mL and grown in batch in suspension in an incubator maintained at 37 °C with a 5% CO<sub>2</sub> overlay, with supplements only as indicated by experimental design below. Cell count measurements were taken every two days using a hemocytometer. Metabolite (glutamine, glucose, glutamate and lactate) concentrations, media pH, and osmolality were measured using a Bioprofile 100+ analyzer (Nova Biomedical, Waltham, MA, USA). Antibody titer was measured with an Agilent 1200 HPLC instrument using 1X PBS buffer on a Thermo Scientific MAbPac Protein A chromatography column (12 micron particle size, 35  $\times$  4.0 mm I.D., Thermo Fisher Scientific, Waltham, MA, USA).

#### 2.2. Experimental Design

The shake flask experiments were conducted according to a  $(2^2, 3^2)$  mixed level experimental design for the following factors: (i) MnCl<sub>2</sub> concentration (high and low levels); (ii) EDTA concentration (high and low levels); (iii) time of addition of MnCl<sub>2</sub> (high, intermediate, and low levels); and (iv) time of addition of EDTA (high, intermediate and low levels). The concentration of MnCl<sub>2</sub> in the basal media corresponds to the low-level condition (-1) for MnCl<sub>2</sub>, while the high-level condition (+1) corresponds to the final concentration of MnCl<sub>2</sub> supplemented media (0.04 mM). High and low levels for MnCl<sub>2</sub> were-based upon previous experiments performed using the same cell line [30]. Similarly, the low-level condition (-1) for EDTA corresponds to "no EDTA" added to the media, while the high level (+1) corresponds to 0.08 mM EDTA added to the media. MnCl<sub>2</sub> and EDTA are added on day 0 (D0), day 3 (D3), or day 6 (D6) after inoculation, corresponding respectively to the low (-1), intermediate (0), and high (+1) levels. Thus, this full factorial mixed level  $(2^2, 3^2)$  experimental design yields a total of 36 different possible shake flask conditions to be tested. However, the 36 conditions are not unique because some of the cases correspond to identical experimental conditions. For instance, 9 of the 36 conditions correspond to MnCl<sub>2</sub> and EDTA at low levels (-1), with the time of addition at

Antibodies 2018, 7, 1 4 of 21

low (-1), intermediate (0) and high levels (+1). The low level condition for MnCl<sub>2</sub> represents basal concentrations, while the low level for EDTA represents no EDTA supplementation. Thus, these 9 cases represent identical conditions where the flask has basal levels of MnCl<sub>2</sub> with no EDTA supplementation either on D0, D3, or D6. A single flask (F1) was used for all nine cases and was treated as the control flask because of what the conditions represent—basal level of MnCl<sub>2</sub> and no EDTA supplementation on any day. It can be shown that there are in fact only 16 unique experimental cases/conditions, as listed in Table 1. Each condition was tested with two biological replicates. The glycan distribution profile was determined using the permethylation assay described below, and the resulting relative glycan percentages data obtained for each condition were analyzed in MINITAB using standard analysis of variance (ANOVA) to obtain the factor effects/coefficients and associated p-values.

Experimental Condition	MnCl <sub>2</sub> Conc. (mM)	EDTA Conc. (mM)	Time of Addition of MnCl <sub>2</sub> <sup>1</sup>	Time of Addition of EDTA <sup>1</sup>	Label
1	0.01	0	D0	D0	Control
2	0.01	0.08	D0	D0	ED D0
3	0.04	0.08	D0	D0	Mn D0/ED D0
4	0.04	0.08	D3	D0	Mn D3/ED D0
5	0.04	0.08	D6	D0	Mn D6/ED D0
6	0.01	0.08	D0	D3	ED D3
7	0.04	0.08	D0	D3	Mn D0/ED D3
8	0.04	0.08	D3	D3	Mn D3/ED D3
9	0.04	0.08	D6	D3	Mn D6/ED D3
10	0.01	0.08	D0	D6	ED D6
11	0.04	0.08	D0	D6	Mn D0/ED D6
12	0.04	0.08	D3	D6	Mn D3/ED D6
13	0.04	0.08	D6	D6	Mn D6/ED D6
14	0.04	0	D0	D0	Mn D0
15	0.04	0	D3	D0	Mn D3
16	0.04	0	D6	D0	Mn D6

**Table 1.** Experimental conditions tested in the mixed level factorial design.

#### 2.3. Glycan Permethylation Assay

On day 8 after inoculation, the cells were centrifuged at 3000 rpm for 10 min and the spent media was harvested. The IgG1 antibody was then purified from the spent media using a PhyNexus Benchtop MEA2 system using Protein A chromatography resin packed in a 2 mL PhyTip column (PhyNexus, San Jose, CA, USA). The glycan permethylation assay was then carried out with 100 microgram of the purified antibody using a previously described method [30]. Briefly, the antibody was first digested with trypsin (Promega, Madison, WI, USA) for four hours in an incubator held at 37 °C, followed by enzymatic deglycosylation using PNGase-F (ProZyme, Hayward, CA, USA) for a minimum of 16 h at 37 °C. The free separated glycans were captured on Hypersep Hyper Carb SPE cartridges (Thermo Fisher Scientific, Waltham, MA, USA) and permethylated following the Ciucanu method using methyl iodide and NaOH in the presence of DMSO [32,33]. The permethylated glycans were purified in a liquid-liquid extraction step with chloroform (Sigma Aldrich, St. Louis, MO, USA), dried and resuspended in 80% methanol (Sigma Aldrich, St. Louis, MO, USA). The resuspended glycans were spotted onto a MALDI/TOF plate with a DHB matrix and analyzed using a 4800 MALDI TOF/TOF Analyzer (ABSciex) in positive ion, reflector mode. The data collected using the mass spectrometer was then exported to DataExplorer to obtain the peak heights for the identified glycans (see Supplementary Table S8). The relative glycan distribution in each sample was calculated from the sum of the peak heights for all the identified glycans in that sample.

<sup>&</sup>lt;sup>1</sup> D0, D3 and D6 refer to Day 0, Day 3 and Day 6 after inoculation, respectively.

Antibodies 2018, 7, 1 5 of 21

#### 2.4. Glycosylation Index

For each experimental condition, glycosylation indices were calculated from the relative percentages of individual glycan species [17,34]. For example, the galactosylation index (GI), defined as the percentage of mono- and di-galactosylated species in the total glycan distribution, was determined according to Equation (1):

$$GI = \frac{2 \times G_2 + G_1}{2 \times (G_0 + G_1 + G_2)} \%, \tag{1}$$

where  $G_0$  is the sum of all agalactosylated species,  $G_1$  is the sum of all monogalactosylated species, and  $G_2$  is the sum of all digalactosylated species. Similarly, we calculated the fucosylation index (FI) for each distribution as

$$FI = \frac{F_1}{(F_0 + F_1)}\%,$$
 (2)

where  $F_0$  and  $F_1$  are the sum of all afucosylated and fucosylated species, respectively.

#### 2.5. Controllability Analysis

Using the technique presented in St.Amand et al. [29], we performed controllability analysis to quantify the effect of time dependent media supplementation on the glycosylation profile in mAbs. Briefly, we note first that estimates of factor coefficients obtained after analyzing the mixed factorial design data correspond to the various "process gains", defined as the change observed in the glycan distribution (output),  $\Delta y$ , in response to a unit change in the input factor with which the coefficient in question is associated. By selecting statistically significant factor coefficients (at the significance level of  $\alpha = 0.05$ ) and setting all non-significant coefficients to zero, we generateed the process gain matrix K so that:

$$\Delta \mathbf{y} = \mathbf{K} \Delta \mathbf{u},\tag{3}$$

where  $\Delta u$  represents the change in the input factor. Singular value decomposition of the process gain matrix produces the diagonal singular value matrix,  $\Sigma$ , and the unitary matrices, W and  $V^T$ , that are subsequently used to obtain the orthogonal input ( $\mu$ ) and output ( $\eta$ ) modes, which, along with the corresponding singular values are used to assess controllability.

#### 3. Results

#### 3.1. Early Addition of EDTA Was Detrimental to Cell Growth and Reduces Antibody Titer

Figures 1 and 2 show the effect that introducing media supplements (MnCl<sub>2</sub> or EDTA) at different time points had on viable cell density and final antibody titer, compared to corresponding results obtained from a control flask (F1), which contained MnCl<sub>2</sub> at basal media concentrations and no EDTA (see Figure S2 in supplementary information for the normalized glucose concentration in each shake flask).

Compared to the conditions in the control flask, early addition of EDTA on D0 reduced the cell density significantly, which is consistent with hampered cell growth. However, this effect was offset somewhat by introducing MnCl<sub>2</sub> in addition to EDTA on D0. The average viable cell density (VCD) measured on day 4 for samples in which both MnCl<sub>2</sub> and EDTA were introduced on D0, was  $1.31 \times 10^9$  cells/L, which was nearly three times as large as the value of the VCD in the flasks where only EDTA was added on D0 ( $\sim$ 0.4  $\times$  10<sup>9</sup> cells/L). Introducing MnCl<sub>2</sub> on D3 or D6 after the addition of EDTA on D0 did not improve the VCD. Similarly, when EDTA was introduced on D3, the VCD in samples with no additional MnCl<sub>2</sub> supplementation dropped sharply. By contrast, when the media was supplemented with MnCl<sub>2</sub> on D0 or D3, the VCD was slightly higher than when the media was supplemented with just EDTA on D3. Supplementing the samples with MnCl<sub>2</sub> on D6 after the addition of EDTA did not improve the VCD significantly. In all cases, the observed VCD was generally higher than when EDTA was introduced on D0. Addition of EDTA on D6 had no impact on the VCD,

2.5. Controllability Analysis

Using the technique presented in St.Amand et al. [29], we performed controllability analysis to quantify the effect of time dependent media supplementation on the glycosylation profile in mAbs. Artibodies 2018, 7, 18 Priefly, we note first that estimates of factor coefficients obtained after analyzing the mixed factorial design data correspond to the various "process gains", defined as the change observed in the glycan reistribletion (the pint); Alyintrockyntime to Minfile Stingleinlythes in provident dispute which the deficients for the Minfile Stingleinlythes in the Minfile Minfil

Figure 2 shows the effect of media supplementation on antibody titers. The average mAb titer in the control flask F1 (with no MnCl<sub>2</sub> or EDTA supplementation) was 0.13 g/L. The addition of EVDTA supplementation by as 0.13 g/L. The addition of EVDTA to the presentation of the process of the





Figure 1: Average viable cell concentration data for CHO-K1 cells when (a) EDTA is added by itself on B0 (4), or in the presence of MnCl2 on B0 (1), B3 (1), and B6 (4); (B) EDTA is added by itself on B3 (6), or in the presence of MnCl2 on B0 (1), b3 (2), and B6 (4); (B) EDTA is added by itself on B3 (6), or in the presence of MnCl2 on B0 (1), b3 (2), and B6 (4); (b) EDTA is added by itself on B3 (6), or in the presence of MnCl2 on B0 (1), b3 (2), and B6 (4); (a) and CD (1), b3 (2), b3 (3), and B6 (4); (a) and CD (1), b3 (3), and B6 (4).

Compared to the conditions in the control flask, early addition of EDTA on D0 reduced the cell density significantly, which is consistent with hampered cell growth. However, this effect was offset somewhat by introducing MnCl<sub>2</sub> in addition to EDTA on D0. The average viable cell density (VCD) measured on day 4 for samples in which both MnCl<sub>2</sub> and EDTA were introduced on D0, was  $1.31 \times 10^9$  cells/L, which was nearly three times as large as the value of the VCD in the flasks where only EDTA was added on D0 (~0.4 × 10<sup>9</sup> cells/L). Introducing MnCl<sub>2</sub> on D3 or D6 *after* the addition of EDTA

Antibodies 2018, 7, 1 7 of 21
Antibodies 2018, 7, 1 7 of 22



**Figure 2:** Average antibody titer for the 16 experimental conditions. Mn and ED refer to the media supplements MnCl<sub>2</sub> and EDTA, while D0, D3 and D6 refer to Day 0, Day 3 and Day 6 after inoculation, respectively. Error bars represent the range of biological replicates (n=2).

### 3:2: Early Addition of MnEl3 Alters the Elycan Distribution Significantly

The addition of EDTA and MnCl<sub>2</sub> at different time points altered the glycan distribution, with earlier addition of MnCl<sub>2</sub> having the more significant effect. Figure 3 shows the effect of media supplementation on select glycan species, with panels 3(a), (b) and (c) showing the changes in the glycan profile as a result of media supplementation with EDTA on B0, B3, and B6, with or without additional MnCl<sub>2</sub> supplementation, and 3(d) showing the impact of MnCl<sub>2</sub> addition in the absence of EDTA supplementation. (See Supplementary Information Figure S3 for the average relative glycan percentage of all the glycan species.)

Adding EDTA to the cell culture media on D0 (Figure 3a) decreased the amount of biantennary fucosylated species FA2: By 5.58%, which was offset by a concomitatil Addie as in its galactosylated isoforms, FA2G1 (4.52%) and FA2G2 (4.52%). (See supplementary information Table S1 to Salva Complete list of experimentally observed glycan species and their structures.) The mannosylated species M5 also increased by 1.52%, with a corresponding reduction of 1.9% in the concentration of the biantennary greep A2 (which is produced from M5 in the Golgiocompartment). Adding MnCl<sub>2</sub> on D0, D3, or D6 o media in which EDTA was introduced on D0 resulted in a further increase in the relative concer trations of the galactosylated isoforms FA2G and FA2G2, in addition to a decrease in the relative percentage of FA2, A2, and A2G1 species, compared to the distribution in the control flask. However, the increase in FA2C1 and FA2G2 was more pronounced when MnCl<sub>2</sub> was introduced on D3 or D6 after adding EDTA When EDTA was added on D3 (Figure 3b) the relative percentages of the biantennary species FA2, FA2G1, and A2G1 decreased, while the relative percentages of glycan species M5, A1, and FA1 increased. When MnCl<sub>2</sub> was added on D0 followed by EDTA supplementation on D3, the concentrations of M5 and FA1 increased, while the concentration of FA2 decreased. Additionally, there was an increase in the relative percentage of A2G1 that was offset by the decrease in the concentration of A1G1. When both EDTA and MnCl<sub>2</sub> were added to the media on D3, the change in the glycan distribution mirrors the trend observed when only EDTA was introduced on D3. The main difference occurs when MnCl<sub>2</sub> was added to the media after EDTA addition, i.e., on D6. Here, the relative percentages of M5, FA1, FA2G1, and FA2G2 increased while the relative percentages of A2, A2G1, and FA2 decreased, similar to the trends observed with the addition of MnCl<sub>2</sub> on D3 or D6 following EDTA supplementation on D0. Although the late addition of EDTA on D6 of the cell culture did not affect the glycan profile significantly (Figure 3c), for those glycan species whose relative

ED D0 + ED D3 + ED D6 +

**Figure 2.** Average antibody titer for the 16 experimental conditions. Mn and ED refer to the media supplements MnCl<sub>2</sub> and EDTA, while D0, D3 and D6 refer to Day 0, Day 3 and Day 6 after inoculation, respectively. Error bars represent the range of biological replicates (n = 2).

Antibodies 2018, 7, 1 8 of 21

#### 3.2. Early Addition of MnCl<sub>2</sub> Alters the Glycan Distribution Significantly

percenting extriting of the Technical with an interest time a with the patricular distribution and parties are distingular to the patricular provided and provide




Figure 3: Average relative glycan percentage of select IgG1 glycans produced in EHO-K1 cells when:
(a) EDTA-is added on DO with no MnG12 supplementation or with MnG12 supplementation on BO, B3, and DO; (b) EDTA-added on DO with hom MnC12 supplementation on BO, B3, and DO; (b) EDTA-added on DO with hom MnC12 supplementation on BO, and DO; (d) EDTA-added on DO with hom MnC12 supplementation on BO, and DO; and DO;

Adding EDTA to the cell culture media on D0 (Figure 3a) degreased the amount of biantenary functions of the growth of the growth of the growth of the control was offset by a Adding MnC1 on D0 decreased the relative isoforms. FA2C1 (4.52%) and FA2C2 (1.52%) and FA2C3 (1.52%) and the galactosylated species A2 (which increased by 1.52%) and the galactosylated species A2 (which increased by 1.52%) and the galactosylated biantenary species A2 (which increased by 1.52%) and the galactosylated biantenary species A2 (which increased by 1.52%). It is relative concentrations of the galactosylated isoforms FA2C3 and FA2C3 in addition to a decrease in the relative percentage of FA2 A2 and A2C3 species compared to the distribution in the control shake flask) is consistent with the trend previously observed in experiments performed using the same flask is consistent with the trend previously observed in experiments performed using the same flask is consistent with the trend previously observed in experiments performed using the same flask is consistent with the trend previously observed in experiments performed using the same flask is consistent with the trend previously observed in experiments performed using the same flask is consistent with the trend previously observed in experiments performed using the same flask is consistent with the trend previously observed in experiments performed using the flast percentages of the biantenary specie

Antibodies 2018, 7, 1 9 of 21

(which increased by 10.20%), the mannosylated species M5 (increasing by 6.59%) and only a marginal increase in the A2G1 species (by 0.76%). Adding MnCl<sub>2</sub> during the peak exponential phase (D6) produced similar changes in the glycan distribution, but these changes were smaller in comparison to the changes in the glycan distribution due to earlier addition of MnCl<sub>2</sub>. The concentrations of the fucosylated species FA2 and FA2G1 decreased by 2.36% and 1.28% respectively, with the corresponding increases in the concentrations of A2 and M5 species being 2.52% and 1.94%, respectively.

While such qualitative discussions of the glycan distribution profiles may be instructive in general, for our purposes in this work, a quantitative analysis relating the changes in the experimental conditions to the observed changes in the glycan profile is more informative.

## 3.3. The Type of Media Supplement and the Time of Addition both Showed Statistically Significant Effects on Glycan Distribution

The concentrations of MnCl2 and EDTA and the time of addition of each one constitute the four factors in the  $(2^2, 3^2)$  mixed factorial experimental design used in this study. In general, the full complement of this factorial experimental design consists of  $4 \times 9 = 36$  independent experimental conditions, and the resulting model, in principle, consists of 35 main and interaction effects. The statistically significant factor coefficients (at the significance level of  $\alpha = 0.05$ ) estimated using ANOVA, were used to generate a "gain" matrix (see Table S3 in Supplementary Information), whose elements represent "by how much" each output variable (relative glycan distribution) will change in response to a unit change in each input factor, including multi-factor interactions (since multiple combinations of single inputs are considered as valid inputs in this case). However, in this case, the full factorial experiment consists of only 16 unique cases (see Materials and Methods); consequently, eliminating the redundant rows in our gain matrix resulting in a reduced gain matrix with 15 input factors, some of which are multi-factor combinations (see Supplementary Information Table S4). Figure 4 shows a heat map of the elements of the gain matrix, indicating which input factor affects which glycan. The input factors include both main effects such as the concentration of media supplements (EDTA, MnCl<sub>2</sub>), times of addition (Mn T1, ED T1, etc.) as well as interaction effects, such as those between the times of addition (e.g., Mn T1-ED T1) or between concentration and the times of addition (e.g., EDTA—Mn T2, EDTA—Mn T1—ED T2, etc.). The colors indicate the direction of the effect (green for increase; red for decrease) and the intensity indicates magnitude.

An examination of the heat map indicates that the glycan species FA2, FA2G1, and A2 are affected by most of the factors and their combinatorial interactions. For instance, the concentration of the most abundant glycoform, FA2 (which accounts for nearly 52% of the glycan concentration in the control sample), is affected by the concentration of MnCl<sub>2</sub>, the two-way interaction of MnCl<sub>2</sub> and EDTA, and the late stage addition of MnCl<sub>2</sub>. In particular, a unit change in the concentration of MnCl<sub>2</sub> causes an increase in the average concentration of FA2 (as indicated by the positive coefficient for the MnCl<sub>2</sub> effect), while introducing MnCl<sub>2</sub> on D3 causes a reduction in the average concentration of FA2. By contrast, the monogalactosylated form FA2G1 is not affected by changes in the media concentration of MnCl<sub>2</sub>; rather it is influenced by changes in the concentration of EDTA, the early addition of MnCl<sub>2</sub>, and the two-way interaction of MnCl<sub>2</sub> and EDTA. Further, we observe that two of the interaction factors, Mn T1-ED T1 and Mn T2-ED T1, have statistically significant and opposing effects on the concentration of FA2G1. The factor Mn T1-ED T1 represents the two-way interaction of adding MnCl2 on D0 and adding EDTA on D0, whereas Mn T2-ED T1 represents the two-way interaction of adding MnCl2 on D3 when EDTA is introduced on D0. We observe therefore that the concentration of FA2G1 is affected by multiple input factors, including complex interactions between the amount of supplements added, and the times of addition of the supplements. One is thus able to assess the impact of each input factor on the response of all other individual glycan species in similar fashion. As indicated by the heat map, the effects of higher order interactions on most of the glycan species are negligible (if they exist at all) because estimates of the coefficients associated with most interaction effects are not statistically significant.

Antibodies 2018, 7, 1 10 of 21
Antibodies 2018, 7, 1 10 of 22




Figure 4-1 Heat map of significant factor coefficients ( $\kappa=0.05$ , see Table S3 for details) obtained from experimental data analysis susings ANOVA. The input factors are on the horizontal laxis, and individual gays are precise on the horizontal laxis and individual gays are precise on the horizontal laxis are precise on the horizontal laxis are precise on the horizontal laxis are precise o

4. Discussion of the heat map indicates that the glycan species FA2, FA2G1, and A2 are affected by most of the factors and their combinatorial interactions. For instance, the concentration of the Most abthroad disjoint of the profile count is not the above the street of the profile of th outhorsalling, tributes of my he succentration by when the two to the introduction where dial supprementation rates in the state of the st entraised at entrained and the entrainment of the control of the c nvidicis unplementa et different tip vancints during sell sulture does in fact heve geneffect on real express. conditions and antihody glycosylation distribution and the effects can be quantified is lobally need a Protectially tise of wheelen effective control schemes changes in the concentration of EDTA, the early add Apecifically Cyc have above that earlier addition on EDTA in the period that earlier addition on EDTA in the period to the appear of the appear of the period of the p ina dacrease in cartife, dyntiter. EMPER ENTANYES EDDEN, nave Statistica investigation at ascat the positive viable sell density. (A.C.P.) tremained 2019 of the the seeding idensity in disating a harmoring of seel growth of Talia result is consistent with attrive leterow on foot, that the PETA visit oxic tencers is lead to start of the Talia result is consistent with attrive leterow on foot, that the PETA visit oxic tencers is lead to start of the Talia result is consistent. viable actilities of write 12 DTAD3 delitions during the arrayeth or door over absorbe attributed that the represal ration by tracemental reaction to the contribution of the (and ansult not FRTA's eshelating after the Bincontrast of when that he FRTA and Mache. Worke added and Prothesese the Copiecropes champaiglid call bile their espain se CP ain lower than other period. The cite in control r flash (5.7.8A) illdicalled my in the increase the ehility can be netributed to the the ibresence of each My Clan tispating and Tagnegulting inerclused cutotoxicities when a ED Tagnes addictions associated by microist the middle of the growth phase and the addition of the cytotoxic EDTA hampered further growth, leading to a steep decline in the cell viability beyond D3 (Figure 1b). By contrast, when MnCl<sub>2</sub> was atldbisdustionmedia (on D0 or D3) in the presence of EDTA, the cells did not experience a similar reduction in viability. When EDTA was added on D6, the cells were already at the end of the growth While the addition of specific media supplements has been studied widely for its effect on the phase and hence the introduction of FDIA drd not alter the cell viability. However, unlike the other quality attributes of mAbs, such studies have been limited to the introduction of media supplements eases where EDIA addition on D0 or D3 resulted in low titers, adding EDIA on D6 along with MnCl2 exclusively at the start of the culture, and the results, when quantitative have yielded only isolated supplementation on D0, D3 or D6, resulted in end of run (EOR) titers higher than the titer value single factor relationships. The results from the current study, show that introducing media in the control flask. The increase in antibody titer in the presence of EDIA was observed by others supplements at different time points during cell culture does in fact have an effect on cell growth as well [36,37] and is attributed to the inhibition of antibody reduction during cell lysis. Further, conditions and antibody glycosylation distribution, and the effects can be quantified globally and potentially used to design effective control schemes.

Antibodies 2018, 7, 1 11 of 21

analyzing the EOR titer data using ANOVA shows that the factor coefficients for the concentration of EDTA, the concentration of MnCl<sub>2</sub>, and time of addition of EDTA are all statistically significant (at a significance level of  $\alpha = 0.05$ ). The expected change in the EOR titer in response to a unit change in any of these factors is quantified by the magnitude of that factor coefficient, while the sign of the factor coefficient indicates the direction of change. Thus, for example, a unit positive step change in the concentration of EDTA (with a factor coefficient of -0.017) or time of addition of EDTA (factor coefficient -0.032) results in a decrease in EOR titer; a unit positive step change in the concentration of MnCl<sub>2</sub> (factor coefficient 0.008) causes an increase in titer. Quantifying the effect of these input factors on the EOR titer provides a rational basis for selecting which particular supplement to add, and how much of it to add, at a given stage of cell culture in order to maximize product yield. However, any media supplementation strategy must meet not just the desired specifications for final titer but also for product quality, i.e., to be effective, the implemented media supplementation strategy must not alter the glycan distributions significantly.

The EOR titer represents the total amount of antibody accumulated at the end of the batch, while the measured glycan distribution represents the relative amount of each individual glycan isoform that has accumulated over the duration of the batch. Now, the relative amount of individual glycan species is a function of antibody productivity and it changes over the course of the batch. In our case, the addition of different media supplements at different stages of batch cultures affected both viability and antibody titer; consequently, the observed change in the glycan distribution has been induced by dynamic media supplementation and changes in productivity. To develop a mechanistic understanding of the effect of dynamic media supplementation on the glycosylation profile, therefore, we first decouple the effect of antibody productivity on the glycan distribution from the overall change observed at the end of the batch. One such decoupling approach involves estimating the mass fractions of specific glycoforms produced at different stages of cell culture using the expression [38]:

$$f_{i} = \frac{\left[ mAb_{i}|_{t=t_{1}} \right] - \left[ mAb_{i}|_{t=t_{2}} \right]}{\left[ mAb_{Tot}|_{t=t_{1}} \right] - \left[ mAb_{Tot}|_{t=t_{2}} \right]},$$
(4)

for  $f_i$ , the fraction of mAb glycoform i produced in the time period [ $t_1$ ,  $t_2$ ] relative to the total amount of antibody secreted in the same period. However, we cannot use this expression for our purpose because we only measured EOR titer and final glycan distribution, not intermittent antibody titer or glycan concentration. Consequently, we propose an alternative metric-based solely on the final titer and glycan measurements.

To illustrate, consider the glycan distribution in the control flask and in the flask with  $MnCl_2$  added on D6. In both flasks, the cell growth profile and antibody productivity will be the same until Day 6, when  $MnCl_2$  is introduced to the latter flask. Thus, the amount of *i*th glycoform fractions accumulated between Day 6 (D6) and the end of the run (EOR) for the two flasks can be written as:

$$f_{Mn6/i} = \frac{\left[ mAb_{Mn6/i}|_{t=EOR} \right] - \left[ mAb_{Mn6/i}|_{t=D6} \right]}{\left[ mAb_{Mn6/Tot}|_{t=EOR} \right] - \left[ mAb_{Mn6/Tot}|_{t=D6} \right]},$$
(5)

$$f_{\text{control/i}} = \frac{\left[ \text{mAb}_{\text{control/i}}|_{t=\text{EOR}} \right] - \left[ \text{mAb}_{\text{control/i}}|_{t=\text{D6}} \right]}{\left[ \text{mAb}_{\text{control/Tot}}|_{t=\text{EOR}} \right] - \left[ \text{mAb}_{\text{control/Tot}}|_{t=\text{D6}} \right]},$$
(6)

Recognizing that the D6 values in Equations (5) and (6) above are identical, we can eliminate the intermittent time point by simple arithmetic manipulations and obtain the change in the accumulation of the *i*th glycoform-based solely on EOR values, as:

$$\Delta f_{i} = \frac{\left[ \text{mAb}_{\text{Mn6/i}} \right]_{t=\text{EOR}} - \left[ \text{mAb}_{\text{control/i}} \right]_{t=\text{EOR}}}{\left[ \text{mAb}_{\text{Mn6/Tot}} \right]_{t=\text{EOR}} - \left[ \text{mAb}_{\text{control/Tot}} \right]_{t=\text{EOR}}},$$
(7)

 $[\text{IIIAD}_{\text{control}/Tot}|_{t=\text{EOR}}]^{-[\text{IIIAD}_{\text{control}/Tot}|_{t=\text{D6}}]$ 

Recognizing that the D6 values in Equations (5) and (6) above are identical, we can eliminate the intermittent time point by simple arithmetic manipulations and obtain the *change* in the accumulation of the *i*th glycoform-based solely on EOR values, as:

Antibodies 2018, 7, 1
$$\Delta f_{i} = \frac{\left[\left.\left.\left.\left.\left(\operatorname{mAb_{Mn6/i}}\right|_{t=EOR}\right) - \left.\left.\left(\operatorname{mAb_{control/i}}\right|_{t=EOR}\right)\right.\right]}{\left.\left.\left.\left(\operatorname{mAb_{Mn6/Tot}}\right|_{t=EOR}\right] - \left.\left.\left(\operatorname{mAb_{control/i}}\right|_{t=EOR}\right]\right.\right)}$$
(7)

Thus, this fractional difference and was us to group to gether different experimental conditions with similar antibody titers, making it possible to compare final algorithm and denote a quitify the effective individual media. Supplemental emphasion by the opposite profile appring rightly by the experimental conditions with similar antibody titers, making it possible to compare final algorithm and hence a quitify the effective individual media. Supplemental entire and the entire experimental conditions with similar antibody titers, making it possible to compare final algorithm. Supplemental conditions with similar antibody titers, making it possible to compare final algorithm. Supplemental conditions with similar antibody titers, making it possible to compare final algorithm. The entire of the compare final algorithm and the entire conditions with similar antibody titers, making it possible to compare final algorithm. The entire conditions with similar antibody titers, making it possible to compare final algorithm and the entire conditions with similar antibody titers, making it possible to compare final algorithm and the entire conditions with entire conditions with similar antibody titers, making it possible to compare final algorithm and the entire conditions with the




Figure 5. Fractional difference in glycoform distribution due to (a) MnCl<sub>2</sub> addition on D0 (cross-Figure 5. Fractional difference in glycoform distribution due to (a) MnCl<sub>2</sub> addition on D0 (cross-Figure 5. Fractional difference in glycoform distribution due to (a) MnCl<sub>2</sub> addition on D0 (cross-hatched), D3 (red bar), and D6 (blue bar) after EDTA addition on D0, relative to the baseline distribution in EDTA D0 supplemented flask; (b) MnCl<sub>2</sub> addition on D3 (cross-hatched), and D6 (red) glycan distribution in EDTA D3 supplemented flask; (b) MnCl<sub>2</sub> addition on D3 supplemented (red) after EDTA addition on D3 relative to the baseline glycan distribution in EDTA D3 supplemented (red) after EDTA addition on D3 relative to the baseline glycan distribution in EDTA D3 supplemented flask, and MnCl<sub>2</sub> addition on D6 after EDTA addition on D6 (blue) relative to the baseline glycan distribution in EDTA D6 supplemented flask; (c) EDTA addition on D6 after MnCl<sub>2</sub> addition on D6 (red) and D3 (blue) relative to the respective glycan distributions due to MnCl<sub>2</sub> addition on D6 and D3. (blue) relative to the respective glycan distributions due to MnCl<sub>2</sub> addition on D6 and D3. (blue) relative to the respective glycan distributions due to MnCl<sub>2</sub> addition on D6 and D3. (blue) relative to the respective glycan distributions due to MnCl<sub>2</sub> addition on D6 and D3. (blue) relative to the respective glycan distributions due to MnCl<sub>2</sub> addition on D6 and D3. (blue) relative to the respective glycan distributions due to MnCl<sub>2</sub> addition on D6 and D3. (blue) relative to the respective glycan distributions due to MnCl<sub>2</sub> addition on D6 and D3. (blue) relative to the respective glycan distributions due to MnCl<sub>2</sub> addition on D6 and D3. (blue) relative to the respective glycan distributions due to MnCl<sub>2</sub> addition on D6 and D3.

A comparison of the fractional difference in the glycan distribution in flasks where MnCl<sub>2</sub> is added to D0 EDTA supplemented flasks relative to the glycan distribution in D0 EDTA supplemented flasks (Figure 5a), shows the following: an increase in the amount of FA2 (by nearly 50% in all cases), FA2G1 (by 29% during D0 supplementation, 60% during D3 supplementation, and 122% during D6 supplementation), and FA2G2 (by 3%, 10%, and 20% respectively), with a relative decrease in A2 and M5 by 2% and 4% when MnCl<sub>2</sub> is added on D3, and nearly 14% when MnCl<sub>2</sub> is added on D6. A similar trend is observed in the fractional difference in the glycan distribution in flasks where MnCl<sub>2</sub> is added on D3 and D6 to D3 EDTA supplemented flasks, and when MnCl<sub>2</sub> is added on D6 to D6 EDTA supplemented flasks (Figure 5b). Again, we notice an increase in FA2, FA2G1 and FA2G2, with a decrease in A2, M5, and A2G1 observed only when MnCl<sub>2</sub> is added on day 6 after the addition of EDTA on D3. Previous studies have shown that adding MnCl<sub>2</sub> produces an upregulation

Antibodies 2018, 7, 1 13 of 21

of galactosyltransferase enzymes [30], and subsequently in increased galactosylation [26,27]. Hence, the increase in the amount of FA2G1 and FA2G2 species can be attributed to the effect of late stage manganese addition on the galactosyltransferase enzyme. Figure 5c shows fractional difference when EDTA is added on D6 after MnCl<sub>2</sub> has been added to the culture on D0 and D3. These differences are calculated relative to the glycan distribution observed due to the addition of MnCl<sub>2</sub> on D3 and D6, respectively. We note that the fractional difference in the fucosylated species FA2 and FA2G1 is positive when EDTA is added after MnCl<sub>2</sub> supplementation, indicating that the addition of EDTA increases the concentration of these species relative to their respective concentrations in MnCl<sub>2</sub> supplemented cultures. Also, a comparison of the fractional difference in the glycan distribution when MnCl<sub>2</sub> was introduced on D0, D3, or D6 relative to the glycan distribution in the control flask (Figure 5d), shows that the relative concentrations of FA2 and FA2G1 species decreased in flasks with D0, while late stage addition of MnCl<sub>2</sub> did not have a significant effect on the overall glycan distribution. Taken together, our findings indicate that the latter addition of EDTA reverses the changes in the glycan distribution induced by MnCl<sub>2</sub>.

Fractional difference analysis helps to identify which glycan species are altered as a result of the addition of specific media supplements, but not why those particular glycan species changed. To identify the kinetic mechanisms underlying the changes observed in the glycan distribution upon adding MnCl<sub>2</sub> to the media, we use an existing dynamic mathematical model of glycosylation [39] to simulate the system response under control conditions and when MnCl<sub>2</sub> is added on D0, and obtain predictions of both the control and D0 glycan distributions (see Supplementary Information section S4 for details). The simulation results show that changes in the glycan distribution due to the addition of MnCl<sub>2</sub> can be directly attributed to the changes in the reaction rates associated with the FucT enzyme.

In addition to fractional difference analysis, we use the glycan indices computed for each experimental condition (Table 2), as a metric for quantitative assessment of the change in the final glycosylation profile caused by the addition of different media supplements. Specifically, a comparison of the individual glycan indices for each condition against the corresponding values under control conditions allows us to establish, objectively, that altering the availability of MnCl<sub>2</sub> in the media using a chelating agent reverses the changes in the glycan distribution. While MnCl<sub>2</sub> addition on D0 resulted in a decrease in the fucosylation index from 79.9% in the control flask to 60.5%, we see that subsequent introduction of EDTA on either D0, D3, or D6 reversed that trend. Early stage addition of EDTA on D0 increased the fucosylation index to 82.46%, while adding EDTA on D3 and D6 resulted in fucosylation indices of 78.8%, and 76.5% respectively. Similarly, the decrease in the galactosylation index, upon adding MnCl<sub>2</sub> on D0, from 17.9% in the control flask to 15.8%, could be reversed by subsequently adding EDTA on D3. Adding MnCl<sub>2</sub> to the media on D3 reduced the fucosylation index to 61.9%, but if we then added EDTA on D6, the fucosylation index increased to 77.8%, which is comparable to the value of 79.9% in the control flask. It is important to note however, that the reversal in the glycan indices observed due to the addition of EDTA on D0 and D3 is achieved at the expense of reduced titer and reduced viability, as discussed above. The indication from our results is that changes in the glycan distribution due to MnCl<sub>2</sub> addition can be reversed only when EDTA is added to the media after MnCl<sub>2</sub> addition. Thus, the effect of MnCl<sub>2</sub> supplementation can be reversed, without decreasing productivity, by adding EDTA on D6 to MnCl<sub>2</sub> supplemented media, providing a means of ensuring higher productivity without altering glycan distribution.

Antibodies 2018, 7, 1 14 of 21

<b>Table 2.</b> Galactosylation index	(GI	and fucosylat	tion index (F)	<ol><li>for each</li></ol>	ch experimental condition.

Experimental Condition <sup>1</sup>	Galactosylation Index (GI)	Fucosylation Index (FI)
Control	17.9	79.9
Mn D0	15.8	60.5
Mn D0/ED D0	20.6	82.5
Mn D0/ED D3	18.0	78.8
Mn D0/ED D6	19.3	76.5
Mn D3	15.7	61.8
Mn D3/ED D0	25.2	88.6
Mn D3/ED D3	15.1	73.9
Mn D3/ED D6	18.0	77.8
Mn D6	16.7	76.3
Mn D6/ED D0	24.8	90.3
Mn D6/ED D3	19.9	86.4
Mn D6/ED D6	17.9	77.3
ED D0	21.6	81.0
ED D3	16.5	75.3
ED D6	16.9	77.7

 $<sup>^{1}</sup>$  Mn and ED refer to the media supplements MnCl<sub>2</sub> and EDTA, while D0, D3 and D6 refer to Day 0, Day 3 and Day 6 after inoculation, respectively.

Although such observations as these provide useful qualitative information about the system, they cannot be used to develop an automatic control strategy; that requires a quantitative representation (and hence understanding) of the effects of media supplementation on glycan distribution. Such quantitative representation can be obtained via formal analysis of the experimental data using analysis of variance (ANOVA) to generate the process gain matrix, K, as described in Materials and Methods. Singular value decomposition of the gain matrix K produces a (diagonal) matrix of singular values,  $\Sigma$ , and two unitary matrices, W and  $V^{T}$ . Together these three matrices provide a particularly insightful representation of the process information encapsulated in the gain matrix, **K**: Equation (3) is transformed into a series of *n* individual and independent equations (see [29]) where, in each case, a linear combination of the original process input factors, with weighting coefficients from the matrix W, now constituting an "input mode",  $\mu_i$ , is connected through the associated singular value  $\sigma_i$ , to the corresponding linear combination of the output glycans, (with weighting coefficients from the matrix V), now constituting an output mode  $\eta_i$  [29]. Furthermore, as a result of this decoupling transformation, the magnitude of each singular value naturally quantifies the extent to which the output mode in question will change in response to a change in the corresponding input mode. Thus, the larger the value of  $\sigma_i$ , the greater will be the change in the corresponding output mode  $\eta_i$  as a result of changes in the input mode  $\mu_i$ , so that output modes associated with larger values of  $\sigma_i$  will be more "controllable" than modes associated with smaller values of  $\sigma_i$ .

The first ten singular values ( $\sigma_1$ — $\sigma_{10}$ ) for our experimental system are listed in Table 3 in decreasing order of magnitude. As modes associated with singular values of smaller magnitude are less controllable, we limit our analysis only to those modes that are practically controllable; we do this by using a threshold cutoff value,  $\sigma^*$ , arbitrarily selected to be 0.50 in this example, thereby limiting our analysis to the first five singular values. From a process control perspective, modes associated with singular values below this threshold are considered to be of no practical importance since, for all intents and purposes, they are not controllable.

Antibodies 2018, 7, 1 15 of 21

**Table 3.** Singular values obtained from singular value decomposition of the matrix of significant factor coefficients.

$\sigma_1$	6.22
$\sigma_2$	3.68
$\sigma_3$	2.21
$\sigma_4$	0.80
$\sigma_5$	0.61
$\sigma_6$	0.45
$\sigma_7$	0.41
$\sigma_8$	0.31
$\sigma_9$	0.10
$\sigma_{10}$	0.05

Next, since by definition, each input–output mode pair represents the linear combination of output glycan species that can be controlled by manipulating the specific input factors in the corresponding input mode, the coefficients of each output factor in the output modes and of each input factor in the input modes provide further information about the relative influences exerted by each original input factor on each output factor. Specifically, the coefficient of a particular output factor in a particular mode represents the magnitude by which the relative percentages of those particular glycans will change in response to a unit change in the input mode. On the other hand, the coefficient of a particular input factor in the associated input mode corresponds to the relative contribution of that input factor to the unit change the input mode in question. Thus, the inputs with the largest coefficients in an input mode represent the dominant factors and hence the largest contributors to the influence of that mode, while the output glycans with the largest coefficients in an output mode represent those species whose relative percentages will change the most under the influence of the input modes. The input-output mode pairs and their associated coefficients are shown in Figure 6.

Because it is associated with the largest singular value of  $\sigma_1$  = 6.62, the first output mode  $\eta_1$ is the most controllable output mode. The value of  $\sigma_1$  represents the change in the overall output mode  $\eta_1$  resulting from a unit change in the input mode  $\mu_1$ . For this output mode, we note that the dominant glycan species are A2, with a coefficient of 0.64, followed by FA2G1 (with a coefficient of -0.62), FA2 (-0.38), M5 (0.14), and A1 (0.13), indicating that a unit positive change in the input mode  $\mu_1$  will result in an increase in A2, M5, and A1, accompanied by a decrease in FA2G1 and FA2, each in the amount indicated by the identified coefficients. The biantennary species A2, with the largest coefficient, is the most controllable glycan in the first mode, followed by FA2G1 and FA2. The indicated coupling between the glycans A2, FA2G1, and FA2 makes sense because an increase in the afucosylated glycoforms occurs at the expense of the fucosylated forms, as our experimental results show. The associated input mode  $\mu_1$  is a linear combination of different input factors representing the media supplements MnCl<sub>2</sub> and EDTA as well as the times of their addition. Mode  $\mu_1$  is primarily dominated by the interaction of MnCl2 and EDTA, and the concentrations of EDTA and MnCl2, with associated coefficients -0.58, 0.44, and -0.39 respectively, indicating that the addition of these two media supplements has opposing individual effects on output mode 1. Early stage addition of EDTA and MnCl<sub>2</sub>, denoted by the factors EDT1 and MnT1, with associated coefficients -0.38 and 0.25 respectively, also exert important influences on the first output mode. Based on the different elements that comprise the first input mode, this analysis indicates that one can control the glycans in output mode  $\eta_1$  by adjusting the concentrations of the two supplements at the early stages of the cell culture.




Figure 6. Cont.

Antibodies 2018, 7, 1 17 of 21
Antibodies 2018, 7, 1 17 of 22




Figure 66. Complicit representation of the coefficients associated with the first five input and output modes (with  $w_i \ge 0.5$ ) obtained from coeffoliability and reise. (a) a point and of  $w_i \ge 0.5$ ) obtained from coeffoliability and reise. (a) a point and of  $w_i \ge 0.5$ ) obtained from coeffoliability and reise  $w_i \ge 0.5$ ) obtained from coeffoliability and reise  $w_i \ge 0.5$ ) obtained from the corresponding input and the corresponding and the correspondin

BThe next controllable outnut mode ne is associated with the singular value of a 368, and the linear the most control glycans represented by this mode is dominated by the glycan species If A2G1 uFA2 A2, 1 M5 and FA2G2. The coefficients associated with the regly cansarput in one we note that the dominant? grespectively indicating that a unit positive change in the input a 20de (with ill cause a selective in 21c, as in (1938), hils (0.14), at the arthornally francisperies thad a crease of the increase in 1942 from the arthornal periods. in the ACC and it ACC windicates that porturbations to the input mode war affect the galactory lated species inartial Provide that in grant is the stranger of the provide in the control of t nousput mode the is less than that his 4 horizonal objects by a rest of afficients in model water associated by the the input factors AM, FA2 (with a coefficient of 0.6), the early stage addition of FIDTA denoted by gfactors. FDT1 (with a the exciente of the 47 land land) land, and the interaction resting show! The associated input mode  $\mu_1$  is a linear combination of different input factors representing the media supplement marrivana ed ar the liar the mode of the rest the characteristic and the complete supplement the complete supplement of the complete supplement to the complete supplement the complete supplement to the complete by once intractions of the first years recover, that enemorise in the transfer of the first years and recover that the more representation of the first years and recover that the more representation of the first years and recover that the more representation of the first years and recover the first years and years are the first years and years and years are the first years and years and years are the first years are the first years and years are the first years are the first years and years are the first years are the first years and years are the first years are the years are the first years. And years are the first years are the first years are the years are the years are the years are the coefficients A253, in 944, a send not 505 respectively, 1 identering simultane quality. This indicates that imput stopole menter has upposted in transaction biracter our varieties objet to technic stages a calific profeed or Argical) MARCO mitant decrease in the appeared that are upstream of the session tapears are clear. The input mode 2 H 3 respectively, also exert important influences of the first 65), the interaction of the time care and EDTA that comprise the first input mode, this analysis indicates that one can control the glycans in output mode  $\eta_1$  by adjusting the concentrations of the two supplements at the early stages of the cell culture.

Antibodies 2018, 7, 1 18 of 21

(with coefficient 0.45), and the early stage addition of MnCl<sub>2</sub> denoted by the factor MnT1). In each of the three input modes, the coefficients associated with the interaction effect of MnCl<sub>2</sub> and EDTA indicate the importance of this combination input factor in altering the concentrations of the glycan species associated with the respective modes.

The fourth and the fifth modes are less controllable, as they are associated with singular values of comparatively smaller magnitudes ( $\sigma_4$  = 0.80 and  $\sigma_5$  = 0.61).  $\eta_4$  is dominated by glycans A1, A2, FA1, FA2, FA2G1, and FA2G2, while  $\eta_5$  is dominated by FA1, A2G1, and FA2G2. The input mode  $\mu_4$  is dominated by the interaction effects Mn T2-ED T2 and EDTA\*Mn T2-ED T2 representing the interaction between the time of addition of the media supplements. By contrast, the predominant factors in mode  $\mu_5$  are MnT1 and EDT2, which represent the addition of MnCl2 on D0 and EDTA on D3 respectively.

It is worth mentioning the following facts about the controllability analysis presented here: (i) even though it is a theoretical analysis, the process gain matrix, K (on which the analysis is-based), was obtained entirely from experimental data. The information it contains about how changes in the inputs (amount of supplement added, and time of addition) affect glycan species, come directly from our designed experiments; (ii) Notwithstanding, a follow-up independent experimental validation of the modal analysis predictions (which contributor to which mode is affected in what manner) will be valuable. Such a validation experimental study, which lies outside the intended scope of this current work, is slated for future work. That study's focus will not only be to validate the controllability analysis results; it will also encompass the more consequential design and implementation of a control system to achieve effective control of glycan distribution during a batch.

For now, we note that the controllability analysis provides a data-based quantification of the effect that the addition of specified amounts of particular media supplements and the respective times of addition jointly have on the output glycan distribution at the end of the batch. As discussed above, introducing these media supplements dynamically also results in quantifiable changes in the antibody titer. Thus, the dynamic supplementation strategies discussed here present a challenging problem involving a trade-off between product yield and product quality. To be effective, a control strategy based on these considerations, must therefore be carefully designed to resolve these conflicts appropriately in order to optimize both the titer and the quality simultaneously. These matters will be addressed theoretically and experimentally in a follow up study.

In closing, we note that

- (1) the relationships between time-dependent changes in media supplements and the corresponding changes in glycan distribution are (understandably) complex and not necessarily obvious or easily amenable to qualitative thinking; but
- (2) controllability analysis via singular value decomposition, and the resulting input-output mode pairs determined specifically for our experimental system, using data from carefully designed experiments, have enabled us to identify which input factors are best manipulated, in order to effect changes in the relative percentage of specific glycan species;
- (3) in addition, the coefficients in the equations representing the input and output modes allow us to quantify by how much we expect the glycan species to change in response to specific time-dependent media supplementation actions.

#### 5. Conclusions

There is growing interest in evaluating the role of media supplements, especially MnCl<sub>2</sub>, in modulating glycoform distributions in mAbs. However, most media supplementation studies (where supplements are added to the media before starting the batch) do not take into consideration the impact of introducing media supplements at different stages of cell growth. In this paper, we have presented a systematic approach for evaluating the effects of time dependent media supplementation on the glycan profile, and provided a methodology for quantifying and analyzing the complex effects. Our results show that while it is important to consider which supplements are to be added to the media

Antibodies 2018, 7, 1 19 of 21

in order to alter specific glycan species, when they are to be added is just as important. In addition to this general observation about what to change and when, our results and analysis technique also demonstrate how to quantify "by how much" we can expect specific glycan species to change as a result of the changes in the media supplements.

For instance, we observe that early stage addition of MnCl<sub>2</sub> affects fucosylated species and alters the glycan distribution more significantly than a late stage addition. Similarly, early stage addition of EDTA affects not just the antibody titer, but also the relative percentages of biantennary and galactosylated species; late stage addition of EDTA does not alter the glycan distribution significantly. The glycan distribution profile is also affected by the addition of both EDTA and MnCl<sub>2</sub> to the media at different time points and it is possible to develop a mechanistic understanding of the effect of individual media components on the glycan distribution by studying the fractional difference in the glycan distribution. However, we note that early stage addition of EDTA is detrimental to cell growth and antibody production, while late stage addition of EDTA improves titer with no appreciable effect on glycan distribution. This study does not recommend using EDTA as a media supplement—instead, our work presents a systematic approach to studying the complex interactions between media supplements when introduced at different time points during batch culture. Additionally, our results demonstrate that changes in the glycan distribution profile due to the addition of MnCl<sub>2</sub> are not immutable; they can be reversed by adding EDTA after MnCl<sub>2</sub> has been added to the media. We were able to identify the specific combinations of input factors which, when manipulated, result in quantifiable changes in the relative percentage of specific glycan species via controllability analysis using our experimental data. For the specific experimental system, our analyses show that A2, FA2G1 and FA2 are the most controllable glycan species whose concentrations can be changed by early stage supplementation of EDTA and late stage supplementation of MnCl<sub>2</sub>.

While this work has focused on establishing a rational framework for studying the influence of time-dependent media supplementation on the glycosylation profile, the techniques introduced here can be extended to tackle the complementary problem of designing and implementing appropriate control strategies to achieve desired glycan distribution profiles. Traditionally, the composition of cell culture media is fixed prior to starting the batch. However, we have demonstrated that introducing supplements at different points in time can influence both the productivity and the quality attribute of the antibody. Although we have examined only two specific media components in the current set of experiments, in principle, the systematic approach presented here can be extended easily to other media components such as amino acids, or trace metals. Future work will involve a comprehensive validation study where a control system will be designed on the basis of these results, and implemented on our experimental systems.

**Supplementary Materials:** The following are available online at http://www.mdpi.com/2073-4468/7/1/1/s1, Table S1: Experimentally observed glycan species and their masses; Table S2: Full factorial experimental design table; Table S3: Gain matrix generated from statistically significant ( $p \le 0.05$ ) coefficients obtained from ANOVA of the full factorial design experimental data; Table S4: Main and interaction effects and corresponding confounding factors; Table S5: "Reduced" gain matrix (**K**) obtained by eliminating the redundant rows from the gain matrix listed in Table S3; Table S6: Unitary matrix **W** obtained from SVD of gain matrix **K**; Table S7: Diagonal matrix of singular values (**Σ**) obtained from SVD of reduced gain matrix **K**; Table S9: Reaction rules for generating the glycan reaction network used in simulations of the dynamic glycosylation model; Table S10: Enzyme and co-substrate concentrations used in the simulations of the dynamic glycosylation model; Figure S1: Comparison of experimental data and model fit for the glycan distribution profile obtained from (a) control flask; and (b) when MnCl<sub>2</sub> is added on D0; Figure S2: Normalized glucose concentration data for each condition tested; Figure S3: Average relative glycan percentage of IgG1 glycans produced in CHO-K1 cells.

**Acknowledgments:** The authors thank Life Technologies (Thermo Fisher Scientific) for donating custom media for this work, and Leila Choe at the Delaware Biotechnology Institute (Newark, DE, USA) for help with the mass spectrometry experiments and for extensive discussions on MALDI data analysis. The authors are also grateful for support from the National Science Foundation via grant # NSF-CBET 1034213.

**Author Contributions:** D.R., A.R. and B.O. conceived the paper; D.R. performed the experiments; D.R., A.R. and B.O. analyzed the data and wrote the manuscript.

Antibodies 2018, 7, 1 20 of 21

Conflicts of Interest: The authors declare no conflict of interest.

#### References

- 1. Aggarwal, S. What's fueling the biotech engine? Nat. Biotechnol. 2007, 25, 1097–1104. [CrossRef] [PubMed]
- 2. Aggarwal, S. What's fueling the biotech engine-2012 to 2013. *Nat. Biotechnol.* **2014**, 32, 32–39. [CrossRef] [PubMed]
- 3. Elvin, J.G.; Couston, R.G.; van der Walle, C.F. Therapeutic antibodies: Market considerations, disease targets and bioprocessing. *Int. J. Pharm.* **2013**, 440, 83–98. [CrossRef] [PubMed]
- 4. Reichert, J.M. Marketed therapeutic antibodies compendium. mAbs 2012, 4, 413–415. [CrossRef] [PubMed]
- 5. Kim, J.; Kim, Y.-G.; Lee, G. Cho cells in biotechnology for production of recombinant proteins: Current state and further potential. *Appl. Microbiol. Biotechnol.* **2012**, *93*, 917–930. [CrossRef] [PubMed]
- 6. Kornfeld, R.; Kornfeld, S. Assembly of asparagine-linked oligosaccharides. *Annu. Rev. Biochem.* **1985**, *54*, 631–664. [CrossRef] [PubMed]
- 7. Cumming, D.A. Pathways and functions of mammalian protein glycosylation. *New Compr. Biochem.* **2003**, *38*, 433–455.
- 8. Berger, M.; Kaup, M.; Blanchard, V. Protein glycosylation and its impact on biotechnology. In *Genomics and Systems Biology of Mammalian Cell Culture*; Hu, W.S., Zeng, A.-P., Eds.; Springer: Berlin/Heidelberg, Germany, 2012; Volume 127, pp. 165–185.
- Del Val, I.J.; Kontoravdi, C.; Nagy, J.M. Towards the implementation of quality by design to the production of therapeutic monoclonal antibodies with desired glycosylation patterns. *Biotechnol. Prog.* 2010, 26, 1505–1527.
   [CrossRef] [PubMed]
- 10. Liu, L. Antibody glycosylation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and fc-fusion proteins. *J. Pharm. Sci.* **2015**, *104*, 1866–1884. [CrossRef] [PubMed]
- 11. Read, E.K.; Park, J.T.; Brorson, K.A. Industry and regulatory experience of the glycosylation of monoclonal antibodies. *Biotechnol. Appl. Biochem.* **2011**, *58*, 213–219. [CrossRef] [PubMed]
- 12. Beck, A.; Wurch, T.; Bailly, C.; Corvaia, N. Strategies and challenges for the next generation of therapeutic antibodies. *Nat. Rev. Immunol.* **2010**, *10*, 345–352. [CrossRef] [PubMed]
- 13. Jefferis, R. Glycosylation as a strategy to improve antibody-based therapeutics. *Nat. Rev. Drug Discov.* **2009**, *8*, 226–234. [CrossRef] [PubMed]
- 14. Wacker, C.; Berger, C.N.; Girard, P.; Meier, R. Glycosylation profiles of therapeutic antibody pharmaceuticals. *Eur. J. Pharm. Biopharm.* **2011**, *79*, 503–507. [CrossRef] [PubMed]
- 15. Hossler, P.; Khattak, S.F.; Li, Z.J. Optimal and consistent protein glycosylation in mammalian cell culture. *Glycobiology* **2009**, *19*, 936–949. [CrossRef] [PubMed]
- 16. Yoon, S.K.; Choi, S.L.; Song, J.Y.; Lee, G.M. Effect of culture ph on erythropoietin production by chinese hamster ovary cells grown in suspension at 32.5 and 37.0 degrees *C. Biotechnol. Bioeng.* **2005**, *89*, 345–356. [CrossRef] [PubMed]
- 17. Ivarsson, M.; Villiger, T.K.; Morbidelli, M.; Soos, M. Evaluating the impact of cell culture process parameters on monoclonal antibody n-glycosylation. *J. Biotechnol.* **2014**, *188*, 88–96. [CrossRef] [PubMed]
- 18. Sou, S.N.; Sellick, C.; Lee, K.; Mason, A.; Kyriakopoulos, S.; Polizzi, K.M.; Kontoravdi, C. How does mild hypothermia affect monoclonal antibody glycosylation? *Biotechnol. Bioeng.* **2015**, *112*, 1165–1176. [CrossRef] [PubMed]
- 19. Ahn, W.S.; Jeon, J.J.; Jeong, Y.R.; Lee, S.J.; Yoon, S.K. Effect of culture temperature on erythropoietin production and glycosylation in a perfusion culture of recombinant cho cells. *Biotechnol. Bioeng.* **2008**, *101*, 1234–1244. [CrossRef] [PubMed]
- 20. Gawlitzek, M.; Estacio, M.; Furch, T.; Kiss, R. Identification of cell culture conditions to control n-glycosylation site-occupancy of recombinant glycoproteins expressed in cho cells. *Biotechnol. Bioeng.* **2009**, *103*, 1164–1175. [CrossRef] [PubMed]
- 21. Serrato, J.A.; Palomares, L.A.; Meneses-Acosta, A.; Ramirez, O.T. Heterogeneous conditions in dissolved oxygen affect n-glycosylation but not productivity of a monoclonal antibody in hybridoma cultures. *Biotechnol. Bioeng.* **2004**, *88*, 176–188. [CrossRef] [PubMed]
- 22. Kunkel, J.P.; Jan, D.C.H.; Jamieson, J.C.; Butler, M. Dissolved oxygen concentration in serum-free continuous culture affects n-linked glycosylation of a monoclonal antibody. *J. Biotechnol.* **1998**, *62*, 55–71. [CrossRef]

Antibodies 2018, 7, 1 21 of 21

23. Borys, M.C.; Linzer, D.I.H.; Papoutsakis, E.T. Ammonia affects the glycosylation patterns of recombinant mouse placental lactogen-i by chinese hamster ovary cells in a ph-dependent manner. *Biotechnol. Bioeng.* **1994**, *43*, 505–514. [CrossRef] [PubMed]

- 24. Wong, N.S.C.; Wati, L.; Nissom, P.M.; Feng, H.T.; Lee, M.M.; Yap, M.G.S. An investigation of intracellular glycosylation activities in cho cells: Effects of nucleotide sugar precursor feeding. *Biotechnol. Bioeng.* **2010**, 107, 321–336. [CrossRef] [PubMed]
- 25. Pacis, E.; Yu, M.; Autsen, J.; Bayer, R.; Li, F. Effects of cell culture conditions on antibody n-linked glycosylation—What affects high mannose 5 glycoform. *Biotechnol. Bioeng.* **2011**, *108*, 2348–2358. [CrossRef] [PubMed]
- Gramer, M.J.; Eckblad, J.J.; Donahue, R.; Brown, J.; Shultz, C.; Vickerman, K.; Priem, P.; van den Bremer, E.T.J.;
   Gerritsen, J.; van Berkel, P.H.C. Modulation of antibody galactosylation through feeding of uridine,
   manganese chloride, and galactose. *Biotechnol. Bioeng.* 2011, 108, 1591–1602. [CrossRef] [PubMed]
- Grainger, R.K.; James, D.C. Cho cell line specific prediction and control of recombinant monoclonal antibody n-glycosylation. *Biotechnol. Bioeng.* 2013, 110, 2970–2983. [CrossRef] [PubMed]
- 28. Surve, T.; Gadgil, M. Manganese increases high mannose glycoform on monoclonal antibody expressed in cho when glucose is absent or limiting: Implications for use of alternate sugars. *Biotechnol. Prog.* **2015**, *31*, 460–467. [CrossRef] [PubMed]
- 29. St. Amand, M.M.; Tran, K.; Radhakrishnan, D.; Robinson, A.S.; Ogunnaike, B.A. Controllability analysis of protein glycosylation in cho cells. *PLoS ONE* **2014**, *9*, e87973. [CrossRef] [PubMed]
- 30. St. Amand, M.M.; Radhakrishnan, D.; Robinson, A.S.; Ogunnaike, B.A. Identification of manipulated variables for a glycosylation control strategy. *Biotechnol. Bioeng.* **2014**, *111*, 1957–1970. [CrossRef] [PubMed]
- 31. Brühlmann, D.; Jordan, M.; Hemberger, J.; Sauer, M.; Stettler, M.; Broly, H. Tailoring recombinant protein quality by rational media design. *Biotechnol. Prog.* **2015**, *31*, 615–629. [CrossRef] [PubMed]
- 32. Ciucanu, I.; Kerek, F. A simple and rapid method for the permethylation of carbohydrates. *Carbohydr. Res.* **1984**, *131*, 209–217. [CrossRef]
- 33. Ciucanu, I.; Costello, C.E. Elimination of oxidative degradation during the per-o-methylation of carbohydrates. *J. Am. Chem. Soc.* **2003**, *125*, 16213–16219. [CrossRef] [PubMed]
- 34. Majid, F.A.A.; Butler, M.; Al-Rubeai, M. Glycosylation of an immunoglobulin produced from a murine hybridoma cell line: The effect of culture mode and the anti-apoptotic gene, bcl-2. *Biotechnol. Bioeng.* **2007**, 97, 156–169. [CrossRef] [PubMed]
- 35. Kim, W.H.; Kim, J.-S.; Yoon, Y.; Lee, G.M. Effect of Ca<sup>2+</sup> and Mg<sup>2+</sup> concentration in culture medium on the activation of recombinant factor ix produced in chinese hamster ovary cells. *J. Biotechnol.* **2009**, 142, 275–278. [CrossRef] [PubMed]
- 36. Kao, Y.-H.; Hewitt, D.P.; Trexler-Schmidt, M.; Laird, M.W. Mechanism of antibody reduction in cell culture production processes. *Biotechnol. Bioeng.* **2010**, *107*, 622–632. [CrossRef] [PubMed]
- 37. McAtee, A.G.; Templeton, N.; Young, J.D. Role of chinese hamster ovary central carbon metabolism in controlling the quality of secreted biotherapeutic proteins. *Pharm. Bioprocess.* **2014**, *2*, 63–74. [CrossRef]
- 38. Fan, Y.Z.; Del Val, I.J.; Muller, C.; Lund, A.M.; Sen, J.W.; Rasmussen, S.K.; Kontoravdi, C.; Baycin-Hizal, D.; Betenbaugh, M.J.; Weilguny, D.; et al. A multi-pronged investigation into the effect of glucose starvation and culture duration on fed-batch cho cell culture. *Biotechnol. Bioeng.* 2015, 112, 2172–2184. [CrossRef] [PubMed]
- 39. Del Val, I.J.; Nagy, J.M.; Kontoravdi, C. A dynamic mathematical model for monoclonal antibody n-linked glycosylation and nucleotide sugar donor transport within a maturing golgi apparatus. *Biotechnol. Prog.* **2011**, 27, 1730–1743. [CrossRef] [PubMed]



© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).